Optical calibration of PCR cyclers patented in USA

CYCLERtest has announced that its patent for the optical calibration of quantitative polymerase chain reaction (qPCR) cyclers is now also granted in the USA, and complements similar patents held by CYCLERtest in Europe and Japan.

The traceable Optical Calibration tool and service is “a major breakthrough for molecular diagnostics and life sciences,” according to CEO Tom Hendrikx. “With this advanced technique, variables in qPCR are monitored, minimised and become controllable. This gives laboratories a better understanding of the qPCR process and enables them to expand its capabilities. This method with new developed hardware supercedes non-traceable techniques such as biological testing and crystal colour changes”

The innovative technique is based on the traceable calibration of temperature, optical detection and light of qPCR cyclers (excitation and emission). A truly unique method as these components are not only detected and generated separately but also in relationship to each other. By doing so, the performance of the real-time thermal cycler is monitored and calibrated.

CYCLERtest is a pioneer and global leader in ISO 17025-accredited qPCR cycler calibrations, enabling laboratories to monitor the performance of their thermocyclers according to global quality requirements.



Other news

Upcoming Events

Focus 2019

SEC Glasgow
1-3 May 2019

Respiratory Microbiology - A Day of Inspiration

Royal Air Force Museum, Hendon
16 May 2019

Clinical and Laboratory Haemostasis 2019

The Atrium Conference Centre, Sheffield Hallam University
5-6 June 2019

The Oxford Haematology in Obstetrics Postgraduate Course

St Edmund Hall, Queen's Lane, Oxford OX1 4AR
9-11 September 2019

IBMS Biomedical Science Congress

ICC, Birmingham
22-25 September 2019

Latest Issue

Pathology In Practice

Pathology In Practice

Apr 2019

Reducing exposure to antimicrobial agents

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.